{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:31:31Z","timestamp":1786977091541,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A liquid chromatography\u2013tandem mass spectrometry method with vonoprazan fumarate\u2010d4 as a stable isotope\u2010labeled internal standard was developed and validated aiming at quantification of vonoprazan fumarate in human plasma for a bioequivalence study. Chromatographic separation was achieved by acetonitrile one\u2010step protein precipitation using a gradient elution of 0.1% formic acid aqueous solution and acetonitrile with a run time of 3.65\u2009min. Detection was carried out on a tandem mass spectrometer in multiple reaction monitoring mode via a positive electrospray ionization interface. The multiple reaction monitoring mode of precursor\u2013product ion transitions for vonoprazan fumarate and vonoprazan fumarate\u2010d4 were\n                    <jats:italic>m\/z<\/jats:italic>\n                    346.0\u2009\u2192\u2009315.1 and 350.0\u2009\u2192\u2009316.0, respectively. The linear range was 0.150\u201360.000\u2009ng\/ml. This method was fully validated with acceptable results in terms of selectivity, carryover, lower limit of quantification, calibration curve, accuracy, precision, dilution effect, matrix effect, stability, recovery and incurred sample reanalysis. A successful application of this method was realized in the bioequivalence study of vonoprazan fumarate tablet (20\u2009mg) among healthy Chinese volunteers.\n                  <\/jats:p>","DOI":"10.1002\/bmc.5860","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T05:09:00Z","timestamp":1711948140000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["LC\u2013MS\/MS method for quick detection of vonoprazan fumarate in human plasma: Development, validation and its application to a bioequivalence study"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-0356","authenticated-orcid":false,"given":"Xinyan","family":"Chen","sequence":"first","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"},{"name":"School of pharmacy Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangsu Wangao Pharmaceutical Co., Ltd.  Nantong Jiangsu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhe","family":"Huang","sequence":"additional","affiliation":[{"name":"School of pharmacy Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Xia","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Du","sequence":"additional","affiliation":[{"name":"School of pharmacy Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbang","family":"Wu","sequence":"additional","affiliation":[{"name":"School of pharmacy Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"},{"name":"School of pharmacy Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwei","family":"Jia","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center of Drug Clinical Evaluation Yijishan Hospital of Wannan Medical College  Wuhu Anhui People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300318t"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i14.1550"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13331"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5638"},{"key":"e_1_2_8_7_1","volume-title":"Pharmacopoeia of the People's Republic of China","author":"Chinese Pharmacopoeia Commission National Medical Products Administration","year":"2020"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn311367-20200918-00558"},{"key":"e_1_2_8_9_1","unstructured":"Committee for Medicinal Products for Human Use in European Medicines Agency International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. (2016).Guideline for good clinical practice E6(R2).https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf. Accessed 22 December 2023."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7"},{"key":"e_1_2_8_11_1","unstructured":"European Medicines Agency. (2011).Guideline on bioanalytical method validation. EMEA\/CHMP\/EWP\/192217\/2009.EMA."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17728"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.179556"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","unstructured":"Hou X. Wang J. Du Q. Tian D. Hu N. Liu D. Zhou F. Xie L. Gu L. &Kudou K.(2022).Efficacy and safety of vonoprazan\u2010based quadruple therapy for the eradication of Helicobacter pylori in patients with peptic ulcers: A pooled analysis of two randomized double\u2010blind double\u2010dummy phase 3 trials. PREPRINT (version 1) available at Research Square.https:\/\/doi.org\/10.21203\/rs.3.rs-1837897\/v1","DOI":"10.21203\/rs.3.rs-1837897\/v1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2292112"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.06.001"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01861-z"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13588"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314852"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.9b00947"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314010"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1009"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.4.411"},{"key":"e_1_2_8_25_1","volume-title":"Drug approval review for vonoprazan fumarate (in Japanese)","author":"Pharmaceuticals and Medical Devices Agency of Japan","year":"2014"},{"key":"e_1_2_8_26_1","unstructured":"Pharmaceuticals and Medical Devices Agency of Japan. (2022).Detailed instruction of Takecab\u00ae tablets 10 mg and 20 mg ver. 3 (in Japanese).JP PMDA."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-022-02979-2"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185314"},{"key":"e_1_2_8_30_1","unstructured":"US Food & Drug Administration. (2018).Guidance for industry: Bioanalytical method validation.US FDA."},{"key":"e_1_2_8_31_1","unstructured":"U.S. Food & Drug Administration. (2022).Lable of VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets).US FDA."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5287"},{"key":"e_1_2_8_33_1","unstructured":"World Medical Association. (2013).WMA Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects.https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 22 December 2023."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318365"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.01.051"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5217"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T23:56:08Z","timestamp":1760054168000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/bmc.5860"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5860","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2024-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5860"}}